Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2011-05-02 | The following table shows the compensation paid in fiscal 2010 to the Companys non-employee directors. Kristine Peterson Fees Earned or Paid in Cash $4,402 Option Awards $370,800 Total $375,202 |
| 2012-04-27 | Kristine Peterson joined Amarin as a non-executive director in November 2010. ... The Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson. ... The following table shows the compensation paid in fiscal 2011 to the Company's non-employee directors. Kristine Peterson 36,000. |
| 2013-04-23 | Kristine Peterson joined Amarin as a non-executive director in November 2010. Ms. Peterson has more than 27 years of pharmaceutical industry experience. The Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O’Sullivan and Ms. Peterson. The following table shows the compensation paid in fiscal 2012 to the Company’s non-employee directors. Kristine Peterson: $409,787 in 2012. |
| 2014-04-30 | Kristine Peterson (2010) 54 Director; Audit Committee; Nominating and Corporate Governance Committee (from 2014 AGM); Director compensation: $116,331 |
| 2015-04-24 | The Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson. ... Currently, the Nominating and Corporate Governance Committee is comprised of Mr. O'Sullivan (Chairman), Dr. Ekman and Ms. Peterson. ... The following table shows the compensation paid in fiscal 2014 to the Company’s non-employee directors. Kristine Peterson: $153,361. |
| 2016-04-29 | Kristine Peterson joined Amarin as a non-executive director in November 2010. Ms. Peterson has more than 30 years of pharmaceutical industry experience... The Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson... The Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Dr. Ekman and Ms. Peterson... The following table shows the compensation paid in fiscal 2015 to the Company’s non-employee directors... Kristine Peterson 70,000 146,250 77,486 293,736 |
| 2017-04-21 | Kristine Peterson (2010) 57 Director; The Audit Committee is currently comprised of Mr. Van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson; The Remuneration Committee is currently comprised of Mr. Stack (Chairman), Ms. Peterson and Mr. Van Heek; Director Compensation Table shows Kristine Peterson compensation as $160,008. |
| 2018-04-20 | Kristine Peterson (2010) 58 Director Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson. Remuneration Committee is currently comprised of Mr. Stack (Chairman), Ms. Peterson and Mr. van Heek. Director Compensation Table shows Kristine Peterson fees earned or paid in cash $72,500, stock awards $45,000, option awards $45,005, total $162,505. |
| 2019-04-25 | Kristine Peterson (2010) 59 Director; Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson; Remuneration Committee is currently comprised of Mr. Stack (Chairman), Ms. Peterson and Mr. van Heek; Nominating and Corporate Governance Committee is currently comprised of Mr. O'Sullivan (Chairman), Mr. Zakrzewski and Dr. Ekman; Director Compensation Table shows Kristine Peterson total compensation $272,502. |
| 2020-06-01 | The Audit Committee is currently comprised of Mr. van Heek (Chairman), Mr. O'Sullivan and Ms. Peterson. The Remuneration Committee is currently comprised of Mr. Stack (Chairman), Ms. Peterson and Mr. van Heek. On May 20, 2019, the Company awarded options representing the right to purchase 9,658 ordinary shares and 7,428 restricted stock units to Ms. Peterson in connection with their service on the Board. The total grant-date fair value of each of these awards is $125,034 and $125,013, respectively. The following table shows the compensation paid in fiscal year 2019 to the Company’s non-employee directors: Kristine Peterson Fees Earned or Paid in Cash: $75,000, Stock Awards: $125,013, Option Awards: $125,034, Total: $325,047. |
| 2021-04-29 | Kristine Peterson joined Amarin as a non-executive director in November 2010. She serves on the Audit Committee and the Remuneration Committee. Director compensation table shows total compensation of $768,714 in 2020. |
| 2022-05-24 | The Audit Committee is currently comprised of Ms. Enright (Chairwoman, effective upon her appointment to the Board in May 2022), Mr. van Heek (Chairman until the appointment of Ms. Enright as Chairwoman in May 2022), Mr. O’Sullivan and Ms. Peterson. The Remuneration Committee is currently comprised of Mr. Wold-Olsen (Chairman, effective as of May 2022), Mr. Stack (Chairman until the appointment of Mr. Wold-Olsen in May 2022), Ms. Peterson and Mr. van Heek. The total grant-date fair value of each of these awards is approximately $180,000, based on a closing price of $5.00 on Nasdaq of the ADSs representing the Company’s ordinary shares on the date of grant. Director Compensation Table: Lars G. Ekman, M.D., Ph.D. $100,000 fees earned in cash, $190,000 stock awards, $190,004 option awards, total $480,004; Jan van Heek $97,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $457,503; Patrick J. O’Sullivan $85,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $445,503; Kristine Peterson $84,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $444,503; David Stack $82,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $442,503; Joseph S. Zakrzewski $67,500 fees earned in cash, $180,000 stock awards, $180,003 option awards, total $427,503. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-01-19 | She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. |
| 2019-01-18 | Ms. Peterson received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. |
| 2020-01-17 | Ms. Peterson currently serves on the Boards of Directors of Amarin Corporation plc, ImmunoGen, Inc., Paratek Pharmaceuticals, Inc. and EyePoint Pharmaceuticals, Inc., all of which are public biopharmaceutical companies. She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. We believe that Ms. Peterson is qualified to serve on our board of directors due to her executive management and sales and marketing experience in large pharmaceutical companies and smaller biotechnology companies and her other public company board experience. |
| 2021-01-21 | Kristine Peterson has served as a member of our board of directors since September 2017. Ms. Peterson has over 30 years of senior executive experience in commercial and business leadership roles in the pharmaceutical and biotechnology industry. ... She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. |
| 2022-01-21 | Ms. Peterson received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. We believe that Ms. Peterson is qualified to serve on our board of directors due to her executive management and sales and marketing experience. |
| 2023-01-20 | Ms. Peterson received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. We believe that Ms. Peterson is qualified to serve on our board of directors due to her executive management and sales and marketing experience in large pharmaceutical companies and smaller biotechnology companies and her other public company board experience. |
| 2024-01-26 | She received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. |
| 2025-01-27 | Ms. Peterson received a Master of Business Administration and a Bachelor of Science from the University of Illinois at Urbana-Champaign. We believe that Ms. Peterson is qualified to serve on our Board of Directors due to her executive management and sales and marketing experience. |
Data sourced from SEC filings. Last updated: 2026-02-03